23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Axsome Therapeutics, Inc. › 2025-2026

Axsome Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Axsome Therapeutics, Inc.’s Form 8-K, filed June 9, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 412Asset managers, any item
  • 1,898Fund votes
  • June 5, 2026Meeting date

Results at a glance

Meeting of June 5, 2026: 4 items on Axsome Therapeutics, Inc.’s Form 8-K, filed June 9, 2026: 2 elected · 2 approved.

Dissent

Significant dissent: 2 directors (26.4%, 23.3% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Axsome Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Axsome Therapeutics, Inc.

These tallies are Axsome Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 9, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Axsome Therapeutics, Inc. — official shareholder meeting results, meeting held June 5, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Mark Saad 28,675,654---- 10,286,8224,815,060 74%Elected—
Elect Director: Susan Mahony, Ph.D., MBA 29,892,131---- 9,070,3454,815,060 77%Elected—
2. Ratification of Appointment of Deloitte & Touche LLP 43,278,14714,407484,982 --0 99.9%Approved—
3. Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers 37,818,384777,937366,155 --4,815,060 98%Approved—

Source: Axsome Therapeutics, Inc., Form 8-K, filed with the SEC on June 9, 2026 — read the filing on EDGAR.

How asset managers voted at the Axsome Therapeutics, Inc. 2025-2026 meeting

412 asset managers disclosed a vote on at least one Axsome Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Mark Saad

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD
FOR: 28,675,654WITHHELD: 10,286,822
Details: description as filed, official tally, votes by 105 asset managers

Description as filed by funds: Election of Directors: Mark Saad

Axsome Therapeutics, Inc.’s own tally for this item (“Elect Director: Mark Saad”): 28,675,654 for, 10,286,822 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class II directors until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified.”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 105 asset managers below reported 12,163,702 for, 3,743,159 withheld, 396,743 abstained, 50 not voted.

FORWITHHOLD
FOR: 12,163,702ABSTAIN: 396,743WITHHOLD: 3,743,159NOT VOTED: 50
Largest asset managers voting on “Election of Directors: Mark Saad” at Axsome Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard4,261,2310 3318,661For
Fidelity2,528,1280 013,900For
BlackRock2,051,7000 00For
T. Rowe Price00 0931,652Withhold
Invesco853,9530 00For
First Trust00 0561,179Withhold
MUTUAL FUND SERIES TRUST496,5580 06,438For
Delaware/Macquarie00 0444,493Withhold
Charles Schwab393,4060 0110For
TIAA00 0252,697Withhold
Jackson National212,2710 32,7760Mixed
Putnam190,6570 00For
Principal00 0169,495Withhold
Manager Directed Portfolios168,2400 00For
Brighthouse81,3930 079,391Mixed
Columbia Threadneedle00 0153,831Withhold
John Hancock11,7960 137,4620Mixed
Loomis Sayles00 139,8210Abstain
Franklin Custodian Funds00 0128,461Withhold
Voya00 0116,066Withhold
Waddell & Reed00 0103,315Withhold
Royce93,6620 00For
Equitable58,9010 034,249Mixed
Hartford91,4300 00For
Nuveen00 076,149Withhold

Showing the 25 largest of 105 asset managers. All 105 are in the interactive database (link above).

Elect Director: Susan Mahony, Ph.D., MBA

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 8 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD
FOR: 29,892,131WITHHELD: 9,070,345
Details: description as filed, official tally, votes by 105 asset managers

Description as filed by funds: Election of Directors: Susan Mahony, Ph.D., MBA

Axsome Therapeutics, Inc.’s own tally for this item (“Elect Director: Susan Mahony, Ph.D., MBA”): 29,892,131 for, 9,070,345 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class II directors until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified.”
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 105 asset managers below reported 12,437,850 for, 3,469,184 withheld, 396,570 abstained, 50 not voted.

FORWITHHOLD
FOR: 12,437,850ABSTAIN: 396,570WITHHOLD: 3,469,184NOT VOTED: 50
Largest asset managers voting on “Election of Directors: Susan Mahony, Ph.D., MBA” at Axsome Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard4,263,4960 2916,400For
Fidelity2,528,1280 013,900For
BlackRock2,051,7000 00For
T. Rowe Price00 0931,652Withhold
Invesco853,9530 00For
First Trust00 0561,179Withhold
MUTUAL FUND SERIES TRUST496,5580 06,438For
Delaware/Macquarie00 0444,493Withhold
Charles Schwab393,5160 00For
TIAA00 0252,697Withhold
Jackson National212,2710 32,7760Mixed
Putnam190,6570 00For
Principal00 0169,495Withhold
Manager Directed Portfolios168,2400 00For
Brighthouse81,3930 079,391Mixed
Columbia Threadneedle153,8310 00For
John Hancock11,7960 137,4620Mixed
Loomis Sayles00 139,8210Abstain
Franklin Custodian Funds00 0128,461Withhold
Voya00 0116,066Withhold
Waddell & Reed00 0103,315Withhold
Royce93,6620 00For
Equitable58,9010 034,249Mixed
Hartford91,4300 00For
Nuveen00 076,149Withhold

Showing the 25 largest of 105 asset managers. All 105 are in the interactive database (link above).

Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 37,818,384AGAINST: 777,937

Prior year: 98.5% for (June 6, 2025 meeting) ▼ 0.5 pts

Details: description as filed, official tally, votes by 411 asset managers

Description as filed by funds: To approve, by non-binding advisory vote, the compensation of our named executive officers.

Axsome Therapeutics, Inc.’s own tally for this item (“3. Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers”): 37,818,384 for, 777,937 against — passed, per its Form 8-K filed June 9, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders voted to approve, by non-binding advisory vote, the compensation of the Company's named executive officers.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 104 asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers.” at Axsome Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard4,279,9223 10For
Fidelity2,542,0280 00For
BlackRock2,051,7000 00For
T. Rowe Price931,6520 00For
Invesco853,9530 00For
First Trust561,1790 00For
MUTUAL FUND SERIES TRUST502,9960 00For
Delaware/Macquarie444,4930 00For
Charles Schwab393,5160 00For
TIAA252,6970 00For
Jackson National245,0470 00For
Putnam190,6570 00For
Principal169,4950 00For
Manager Directed Portfolios168,2400 00For
Brighthouse160,7840 00For
Columbia Threadneedle153,8310 00For
John Hancock149,2580 00For
Loomis Sayles139,8210 00For
Franklin Custodian Funds128,4610 00For
Voya116,0660 00For
Waddell & Reed103,3150 00For
RBB FUND, INC.97,9770 00For
Royce93,6620 00For
Equitable93,1500 00For
Hartford91,4300 00For

Fund voting reports, all 104 managers: 16,345,560 for, 5,246 against, 3,589 abstained, 50 not voted, 94 mixed. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 337 asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers.” at Axsome Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity1,646,6030 00For
BlackRock1,606,7518,809 00For
Invesco1,528,6890 00For
T. Rowe Price1,409,7880 00For
GEODE CAPITAL MANAGEMENT, LLC1,163,5440 00For
State Street888,2501,327 00For
Wellington839,0000 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.737,5780 00For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST702,7730 00For
Charles Schwab395,1690 00For
PICTET ASSET MANAGEMENT SA369,3890 00For
Northern Trust360,7492,848 00For
Vanguard358,0260 00For
Nuveen335,7600 00For
Hood River Capital Management LLC311,0380 00For
Putnam285,3610 00For
Citadel266,6150 00For
Loomis Sayles247,9190 00For
PRINCIPAL GLOBAL INVESTORS233,4460 00For
ORBIMED ADVISORS LLC213,9210 00For
PNC BANK, NATIONAL ASSOCIATION201,0480 00For
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND200,3570 00For
Point72199,6710 00For
DE Shaw186,8590 00For
MELLON INVESTMENTS Corp171,1390 00For

Institutional-manager reports, all 337 managers: 19,198,702 for, 358,174 against, 5,429 abstained, 873 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Deloitte & Touche LLP

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 43,278,147AGAINST: 14,407
Details: description as filed, official tally, votes by 104 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026.

Axsome Therapeutics, Inc.’s own tally for this item (“2. Ratification of Appointment of Deloitte & Touche LLP”): 43,278,147 for, 14,407 against — passed, per its Form 8-K filed June 9, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 104 asset managers below reported 16,295,166 for, 3,588 abstained, 50 not voted.

FOR
FOR: 16,295,166ABSTAIN: 3,588NOT VOTED: 50
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING F” at Axsome Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard4,279,9250 00For
Fidelity2,542,0280 00For
BlackRock2,051,7000 00For
T. Rowe Price931,6520 00For
Invesco853,9530 00For
First Trust561,1790 00For
MUTUAL FUND SERIES TRUST502,9960 00For
Delaware/Macquarie444,4930 00For
Charles Schwab393,5160 00For
TIAA252,6970 00For
Jackson National245,0470 00For
Putnam190,6570 00For
Principal169,4950 00For
Manager Directed Portfolios168,2400 00For
Brighthouse160,7840 00For
Columbia Threadneedle153,8310 00For
John Hancock149,2580 00For
Loomis Sayles139,8210 00For
Franklin Custodian Funds128,4610 00For
Voya116,0660 00For
Waddell & Reed103,3150 00For
Royce93,6620 00For
Equitable93,1500 00For
Hartford91,4300 00For
Nuveen76,1490 00For

Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).

Largest Axsome Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 51,459,766 shares outstanding at the time of that meeting.

Fund voting reports: top Axsome Therapeutics, Inc. shareholders by shares voted on “To approve, by non-binding advisory vote, the compensation of our named executive officers.”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 8.32%
2Fidelity 4.94%
3BlackRock 3.99%
4T. Rowe Price 1.81%
5Invesco 1.66%
6First Trust 1.09%
7MUTUAL FUND SERIES TRUST 0.98%
8Delaware/Macquarie 0.86%
9Charles Schwab 0.76%
10TIAA 0.49%
Institutional-manager reports: top Axsome Therapeutics, Inc. shareholders by shares voted on “To approve, by non-binding advisory vote, the compensation of our named executive officers.”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 3.20%
2BlackRock 3.14%
3Invesco 2.97%
4T. Rowe Price 2.74%
5GEODE CAPITAL MANAGEMENT, LLC 2.26%
6State Street 1.73%
7Wellington 1.63%
8ADAGE CAPITAL PARTNERS GP, L.L.C. 1.43%
9NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST 1.37%
10Charles Schwab 0.77%

Reported Axsome Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Axsome Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Herriot Tabuteau, M.D.8,992,422 17.47%Proxy statement (DEF 14A), proxy filed April 24, 2026
Antecip Capital LLC7,344,500 14.27%Proxy statement (DEF 14A), proxy filed April 24, 2026
Vanguard Group4,164,818 8.09%Form 13F, quarter ended March 31, 2026
BlackRock3,912,844 7.60%Form 13F, quarter ended March 31, 2026
FMR (Fidelity)1,566,995 3.05%Form 13F, quarter ended March 31, 2026
T. Rowe Price1,317,059 2.56%Form 13F, quarter ended March 31, 2026
Invesco1,297,678 2.52%Form 13F, quarter ended March 31, 2026
Geode Capital1,162,981 2.26%Form 13F, quarter ended March 31, 2026
Wellington Management1,145,306 2.23%Form 13F, quarter ended March 31, 2026
State Street986,809 1.92%Form 13F, quarter ended March 31, 2026

Percentages above are of 51,459,766 shares outstanding, as reported by Axsome Therapeutics, Inc. on its Form 10-Q dated April 27, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Axsome Therapeutics, Inc.'s shareholder meeting held June 5, 2026, in the 2025-2026 proxy season, 412 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,898 separate fund positions. On the most widely held item on that ballot — To approve, by non-binding advisory vote, the compensation of our named executive officers. — Axsome Therapeutics, Inc.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Axsome Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 9, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Axsome Therapeutics, Inc.’s 10-Q dated April 27, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Axsome Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Axsome Therapeutics (AXSM) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/axsome-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.